35,510 Shares in DaVita Inc. $DVA Purchased by Ieq Capital LLC

Ieq Capital LLC acquired a new position in shares of DaVita Inc. (NYSE:DVA) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 35,510 shares of the company’s stock, valued at approximately $7,900,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of DVA. Root Financial Partners LLC increased its stake in shares of DaVita by 128.0% during the first quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock valued at $29,000 after purchasing an additional 105 shares in the last quarter. Canada Pension Plan Investment Board bought a new stake in shares of DaVita in the 2nd quarter worth approximately $43,000. Caitlin John LLC purchased a new stake in shares of DaVita in the 4th quarter worth approximately $34,000. Sankala Group LLC bought a new position in DaVita during the 4th quarter valued at approximately $39,000. Finally, iSAM Funds UK Ltd bought a new position in DaVita during the 3rd quarter valued at approximately $46,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Insider Transactions at DaVita

In other DaVita news, insider Kathleen Alyce Waters sold 15,405 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the completion of the sale, the insider directly owned 109,194 shares of the company’s stock, valued at approximately $22,756,029.60. This represents a 12.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.90% of the company’s stock.

Wall Street Analysts Forecast Growth

DVA has been the topic of several analyst reports. Weiss Ratings raised DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 5th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $265.00 price target on shares of DaVita in a report on Wednesday, August 5th. Truist Financial lowered their price target on DaVita from $250.00 to $215.00 and set a “hold” rating for the company in a research report on Friday, August 7th. TD Cowen upgraded shares of DaVita from a “hold” rating to a “buy” rating and upped their price target for the stock from $201.00 to $220.00 in a research note on Friday, August 7th. Finally, Oppenheimer set a $220.00 price objective on shares of DaVita in a research report on Friday, August 7th. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $221.75.

DaVita Stock Performance

DVA stock opened at $174.21 on Monday. The business’s 50-day moving average is $214.96 and its two-hundred day moving average is $182.03. The company has a market cap of $11.11 billion, a price-to-earnings ratio of 14.26, a P/E/G ratio of 0.58 and a beta of 0.88. DaVita Inc. has a fifty-two week low of $101.00 and a fifty-two week high of $247.49.

DaVita (NYSE:DVA) last released its quarterly earnings results on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, beating the consensus estimate of $3.88 by $0.14. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The firm had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.50 billion. During the same quarter in the prior year, the firm earned $2.95 EPS. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Equities analysts predict that DaVita Inc. will post 14.57 earnings per share for the current year.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.